All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
On July 16, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of belumosudil (200 mg once daily) for the treatment of adults and pediatric patients ≥12 years with chronic graft-versus-host disease (cGvHD) who have failed ≥2 prior lines of systemic therapy.1 The approval was based on the results of the phase II ROCKstar trial, which were previously published on the GvHD Hub.
Belumosudil was shown to be efficacious, with robust and durable responses, and was well tolerated. This approval makes belumosudil the first and only ROCK2 inhibitor to be approved in the U.S. and therefore represents a new treatment paradigm for patients with cGvHD, including those with difficult-to-treat manifestations like fibrosis.
Positive topline results of belumosudil (KD025) in patients with chronic GvHD
On May 21, positive topline results of the pivotal trial evaluating belumosudil in patients with chronic graft-versus-disease (cGvHD) were announced.
Editorial theme | Latest updates on cGvHD treatment
First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In the case of severe cGvHD, another...
Subscribe to get the best content related to GvHD delivered to your inbox